CT 327

Drug Profile

CT 327

Alternative Names: CT 301/P; CT-327; K-252a-PEG2K; Pegylated K252A; SNA-120

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Cephalon
  • Developer Creabilis SA
  • Class Carbazoles; Indole alkaloids; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis
  • Phase I Neuropathic pain

Most Recent Events

  • 06 Dec 2016 Creabilis SA has been acquired by Sienna Biopharmaceuticals
  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
  • 21 Jul 2015 Phase II development for Plaque psoriasis is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top